Drug intelligence / Profile preview

DWPUR001

Development stage: Phase 2
Administration: Oral

Overview

DWPUR001 is an investigational drug evaluated in combination with tenofovir for the treatment of chronic hepatitis B virus (HBV) infection. Clinical trials have assessed its efficacy and safety when administered alongside tenofovir disoproxil fumarate in patients with HBV. The precise mechanism of action, molecular target, and chemical class of DWPUR001 are not publicly disclosed as of June 2025. It is being studied as an adjunct therapy to standard antiviral treatment for HBV[1][2][5].

Beyond the preview

Go deeper on DWPUR001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWPUR001.

Explore the full profile